DRAP issued guidance on Remote Virtual Inspection (RVI) for GMP Assessment of overseas manufacturing facilities for registration of finished Pharmaceutical Drugs and Biologicals

Ijaz Mustafa Drugs, General September 27, 2022September 28, 2022

Virtual_Inspection_Letter Download

← Minutes of 320th Meeting of Registration Board held on 29th -31st August, 2022
National Task Force (NTF) for Eradication of Spurious and Unregistered Therapeutic goods; CEO DRAP Chaired the meeting of NTF Core Team →